Monopar Therapeutics Inc. (MNPR) Revenue by Segment & Business Profile

Therapeutics for cancer treatment, including ALXN1840 and MNPR-101 was 100.0% of Monopar Therapeutics Inc.'s revenue, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MNPRMonopar Therapeutics Inc.Follow MNPR — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 474.2M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

What the company does

Monopar Therapeutics Inc. is a biotechnology company in the healthcare sector.

Roles we read

from the filings, not the sector label

Clinical-stage developer

Monopar Therapeutics Inc. — questions

What does Monopar Therapeutics Inc. do?: Monopar Therapeutics Inc. is a biotechnology company in the healthcare sector.
How does Monopar Therapeutics Inc. make money?: By the lines it reports in its SEC filings: Therapeutics for cancer treatment, including ALXN1840 and MNPR-101 100.0% of revenue.

Every figure on this page comes from Monopar Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.